Ginkgo Bioworks Ownership
| DNA Stock | USD 6.85 0.55 7.43% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 51.9 M | Current Value 54.2 M | Avarage Shares Outstanding 267.7 M | Quarterly Volatility 565.6 M |
Ginkgo Stock Ownership Analysis
About 79.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.67. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ginkgo Bioworks Holdings recorded a loss per share of 8.91. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 20th of August 2024. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Ginkgo Bioworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 641 people. To learn more about Ginkgo Bioworks Holdings call Jason Kelly at 877 422 5362 or check out https://www.ginkgo.bio.Besides selling stocks to institutional investors, Ginkgo Bioworks also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ginkgo Bioworks' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ginkgo Bioworks' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ginkgo Bioworks Quarterly Liabilities And Stockholders Equity |
|
Ginkgo Bioworks Insider Trades History
About 7.0% of Ginkgo Bioworks Holdings are currently held by insiders. Unlike Ginkgo Bioworks' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ginkgo Bioworks' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ginkgo Bioworks' insider trades
Ginkgo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ginkgo Bioworks is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ginkgo Bioworks Holdings backward and forwards among themselves. Ginkgo Bioworks' institutional investor refers to the entity that pools money to purchase Ginkgo Bioworks' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2025-03-31 | 686.8 K | Millennium Management Llc | 2024-12-31 | 670.1 K | Sb Investment Advisers (uk) Ltd | 2024-12-31 | 610.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 565.3 K | D. E. Shaw & Co Lp | 2024-12-31 | 546.4 K | Bnp Paribas Arbitrage, Sa | 2025-03-31 | 465.2 K | Two Sigma Advisers, Llc | 2025-03-31 | 457.6 K | Geode Capital Management, Llc | 2024-12-31 | 437 K | Ubs Group Ag | 2024-12-31 | 386.3 K | Bank Of America Corp | 2024-12-31 | 3.8 M | Viking Global Investors Lp | 2025-03-31 | 3.6 M |
Ginkgo Bioworks Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ginkgo Bioworks insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ginkgo Bioworks' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ginkgo Bioworks insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ginkgo Bioworks Corporate Filings
F4 | 22nd of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 21st of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of April 2025 Other Reports | ViewVerify | |
| 24th of March 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ginkgo Bioworks Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ginkgo Bioworks' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ginkgo Bioworks Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ginkgo Bioworks Holdings Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ginkgo Bioworks Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.91) | Revenue Per Share | Quarterly Revenue Growth 0.273 | Return On Assets | Return On Equity |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.